Cargando…

Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature

Belimumab is a B-cell depletion therapy that has emerged as an effective and safe treatment option for Systemic Lupus Erythematosus (SLE), but ongoing phase IV trials continue to report its common and rare adverse effects. Our case report seeks to add data to the existing literature on the safety pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Bazigh, Izza, Asfour, Mohamad, Muddassir, Salman, Mughni, Sami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956404/
https://www.ncbi.nlm.nih.gov/pubmed/35345744
http://dx.doi.org/10.7759/cureus.22540
_version_ 1784676561529602048
author Bazigh, Izza
Asfour, Mohamad
Muddassir, Salman
Mughni, Sami
author_facet Bazigh, Izza
Asfour, Mohamad
Muddassir, Salman
Mughni, Sami
author_sort Bazigh, Izza
collection PubMed
description Belimumab is a B-cell depletion therapy that has emerged as an effective and safe treatment option for Systemic Lupus Erythematosus (SLE), but ongoing phase IV trials continue to report its common and rare adverse effects. Our case report seeks to add data to the existing literature on the safety profile of belimumab. We report an interesting and complicated case of a 30-year-old female with a 12-year history of SLE and multiple treatment failures who developed acute pancreatitis in the context of the initiation of belimumab. The temporal link between the two events made us undertake a review of literature on the efficacy and safety of belimumab. We used PubMed and Medline to shortlist eight studies that included phase III parent and extension clinical trials of belimumab that had been conducted in the past 10 years and illustrated the results in a tabulated form.  The United States Food and Drug Administration has approved belimumab as a safe and effective treatment option for SLE. The BLISS-52, BLISS-76, and BLISS-SC trials along with their extension trials showed that SRI (SLE Responder Index) was higher in the patient cohorts that were treated with IV (intravenous) or SC (subcutaneous) belimumab. According to the website “eHealthMe.com”, which tracks the incidence of adverse events from drugs by allowing people to report events, 14100 people reported side effects when taking belimumab and among them, 29 people (0.21%) reported acute pancreatitis. Time on belimumab when patients had acute pancreatitis was 1-2 years for 52% of the patients and 1-6 months for 40% of the patients; 96% of the patients were females. The age group at which it was most reported was 40-49 years. Additional data is needed to enable a better characterization of the pathophysiology and nature of acute pancreatitis as a possible side effect of belimumab.
format Online
Article
Text
id pubmed-8956404
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-89564042022-03-27 Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature Bazigh, Izza Asfour, Mohamad Muddassir, Salman Mughni, Sami Cureus Internal Medicine Belimumab is a B-cell depletion therapy that has emerged as an effective and safe treatment option for Systemic Lupus Erythematosus (SLE), but ongoing phase IV trials continue to report its common and rare adverse effects. Our case report seeks to add data to the existing literature on the safety profile of belimumab. We report an interesting and complicated case of a 30-year-old female with a 12-year history of SLE and multiple treatment failures who developed acute pancreatitis in the context of the initiation of belimumab. The temporal link between the two events made us undertake a review of literature on the efficacy and safety of belimumab. We used PubMed and Medline to shortlist eight studies that included phase III parent and extension clinical trials of belimumab that had been conducted in the past 10 years and illustrated the results in a tabulated form.  The United States Food and Drug Administration has approved belimumab as a safe and effective treatment option for SLE. The BLISS-52, BLISS-76, and BLISS-SC trials along with their extension trials showed that SRI (SLE Responder Index) was higher in the patient cohorts that were treated with IV (intravenous) or SC (subcutaneous) belimumab. According to the website “eHealthMe.com”, which tracks the incidence of adverse events from drugs by allowing people to report events, 14100 people reported side effects when taking belimumab and among them, 29 people (0.21%) reported acute pancreatitis. Time on belimumab when patients had acute pancreatitis was 1-2 years for 52% of the patients and 1-6 months for 40% of the patients; 96% of the patients were females. The age group at which it was most reported was 40-49 years. Additional data is needed to enable a better characterization of the pathophysiology and nature of acute pancreatitis as a possible side effect of belimumab. Cureus 2022-02-23 /pmc/articles/PMC8956404/ /pubmed/35345744 http://dx.doi.org/10.7759/cureus.22540 Text en Copyright © 2022, Bazigh et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Bazigh, Izza
Asfour, Mohamad
Muddassir, Salman
Mughni, Sami
Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature
title Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature
title_full Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature
title_fullStr Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature
title_full_unstemmed Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature
title_short Acute Pancreatitis After the Use of Belimumab in a Patient With Systemic Lupus Erythematosus: Case Report and Review of Literature
title_sort acute pancreatitis after the use of belimumab in a patient with systemic lupus erythematosus: case report and review of literature
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956404/
https://www.ncbi.nlm.nih.gov/pubmed/35345744
http://dx.doi.org/10.7759/cureus.22540
work_keys_str_mv AT bazighizza acutepancreatitisaftertheuseofbelimumabinapatientwithsystemiclupuserythematosuscasereportandreviewofliterature
AT asfourmohamad acutepancreatitisaftertheuseofbelimumabinapatientwithsystemiclupuserythematosuscasereportandreviewofliterature
AT muddassirsalman acutepancreatitisaftertheuseofbelimumabinapatientwithsystemiclupuserythematosuscasereportandreviewofliterature
AT mughnisami acutepancreatitisaftertheuseofbelimumabinapatientwithsystemiclupuserythematosuscasereportandreviewofliterature